Spruce Biosciences, Inc. Accrued Investment Income Receivable
Spruce Biosciences, Inc. (SPRB) had Accrued Investment Income Receivable of $0 as of 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Balance Sheet › Assets
us-gaap:AccruedInvestmentIncomeReceivable · last filed 2023-11-13
- 2023-09-30: Accrued Investment Income Receivable $0.00.
- 2023-06-30: Accrued Investment Income Receivable $0.00.
- 2023-03-31: Accrued Investment Income Receivable $0.00.
- 2022-12-31: Accrued Investment Income Receivable $0.00; Accrued Investment Income Receivable as first filed $100.00K.
| Period end | Accrued Investment Income Receivable | Accrued Investment Income Receivable as first filed |
|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-13 | $100.00K 10-K · filed 2023-03-16 |
| 2022-09-30 | $100.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $135.00K 10-Q · filed 2022-08-10 | |
| 2021-12-31 | $100.00K 10-K · filed 2023-03-16 | $135.00K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |